RxDoctor Payments Data

Taquita Milner

Psychiatric/Mental Health · Denver, NCNPI 1891355970

Payments from drug & device makers

$721in general payments, 2019–2025

Across 38 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$325
  • Supernus Pharmaceuticals, Inc.$85
  • Neurocrine Biosciences, Inc.$76
  • Lundbeck LLC$69
  • Otsuka America Pharmaceutical, Inc.$47
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$44
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$721 in reported general payments places this provider in the 55th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$12,991
Medicare patients
24
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$97,179
VraylarCariprazine Hcl28$46,291
CaplytaLumateperone Tosylate13$20,578
TrintellixVortioxetine Hydrobromide12$10,040
BelsomraSuvorexant16$7,010
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine70$2,590
Lamotrigine ErLamotrigine23$1,982
Vilazodone Hcl16$1,644
Quetiapine Fumarate72$1,278
Bupropion XlBupropion Hcl62$1,258
Duloxetine Hcl70$1,225
Clonazepam149$1,079
Venlafaxine Hcl ErVenlafaxine Hcl38$1,026
Aripiprazole37$1,015
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$76$97,17912 claims
AbbVieVraylar$325$46,29128 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$44$20,57813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Denver

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →